medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 4

<< Back Next >>

Ann Hepatol 2014; 13 (4)

Persistent hepatic encephalopathy secondary to portosystemic shunt occluded with Amplatzer device

Ramírez-Polo A, Márquez-Guillén E, González-Aguirre AJ, Casanova-Sánchez IE, Chávez-Ruiz R, Carrillo-Maravilla E, López-Méndez E

Language: English
References: 28
Page: 456-460
PDF size: 251.31 Kb.


ABSTRACT

Hepatic encephalopathy is a frequent complication of cirrhosis, when this event becomes persistent, treatment compliance should be verified and any precipitating factor need to be identified. Also the presence of portosystemic shunts, which are a rare cause of decompensation or persistence hepatic encephalopathy need to be ruled out. In this paper we report the case of a 57 year old man with persistent hepatic encephalopathy secondary to the presence of a porto-onfalo-femoral shunt successfully closed with the placement of an Amplatzer device.


REFERENCES

  1. Degos B, Daelman L, Huberfeld G, Meppiel E, Rabier D, Galanaud D, Magis AS, et al. Portosystemic shunts: An underdiagnosed but treatable cause of neurological and psychiatric disorders. J Neurol Sciences 2012; 32: 58-64.

  2. Tashiro H, Ide K, Amano H, Kobayashi T, Onoe T, Ishiyama K, Kuroda S, et al. Surgical treatment for portosystemic encephalopathy in patients with liver cirrhosis: Occlusion of portosystemic shunt in combination with splenectomy. Hepatol Res 2012; DOI: 10.1111.

  3. Mukund A, Rajesh S, Arora A, Patidar Y, Jain D, Sarin SK. Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol 2012; 23: 1200-6.

  4. Rahimi RS, Rockey DC. Complications of cirrhosis. Curr Opin Gastroenterol 2012; 28: 223-9.

  5. Khungar V, Poordad F. Hepatic Encephalopathy. Clin Liver Dis 2012; 16: 301-20.

  6. Córdoba J. New assessment of hepatic encephalopathy. J Hepatol 2011; 54: 1030-40.

  7. Córdoba J, Mínguez B. Hepatic Encephalopathy. Semin Liver Dis 2008; 28: 70-80.

  8. Macías-Rodríguez RU, Torre A. Diagnostic approach to persistent hepatic encephalopathy. Rev Gastroenterol Mex 2011; 76: 345-52.

  9. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25.

  10. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Eng J Med 1997; 337: 473-9.

  11. Poh Z, Chang PEJ. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Inter J Hepatology 2012; 480309.

  12. Romero-Gómez M. Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opin Pharmacother 2010; 11: 1317-27.

  13. Wakim-Fleming J. Hepatic encephalopathy: suspect it early in patients with cirrhosis. Cleve Clin J Med 2011; 78: 597-605.

  14. Eroglu Y, Byrne WJ. Hepatic encephalopathy. Emerg Med Clin N Am 2009; 27: 401-14.

  15. Bajaj JS. The modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-47.

  16. Als-Nielsen B, Gluud LL, Gluud C. Non absorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004; 2: CD003044.

  17. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.

  18. van Leeuwen PA, van Berlo CL, Soeters PB. New mode of action for lactulose. Lancet 1988; 1: 55-6.

  19. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, et al. Rifaximin Treatment in Hepatic Encephalopathy. N Engl J Med 2010; 362: 1071-81.

  20. Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, et al; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, doubleblind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-8.

  21. Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012; 18: 767-77.

  22. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-Ornithine-L-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2009; 24: 9-14.

  23. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther 2012; 92: 321-31.

  24. Sicklick JK, D’Angelica. Fong Y. The liver. In: Townsend CM (ed) Sabiston Textbook of Surgery, The Biological Basis of Modern Surgical Practice. 19th. Ed. Philadelphia: Saunders- Elselvier; 2012, p. 1431.

  25. Alonso-Gamarra E, Parrón M, Pérez A, Prieto C, Hierro L, López-Santamaría M. Clinical and radiologic manifestations of congenital extrahepatic portosystemic shunts: a comprehensive review. Radiographics 2011; 31: 707-22.

  26. Kobayashi N, Niwa T, Kirikoshi H, Fujita K, Yoneda M, Saito S, Nakajima A. Clinical classification of congenital extrahepatic portosystemic shunts. Hepatol Res 2010; 40: 585-93.

  27. Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 1996; 11: 51-8.

  28. Boixadera H, Tomasello A, Quiroga S, Cordoba J, Perez M, Segarra A. Successful embolization of a spontaneous mesocaval shunt using the Amplatzer Vascular Plug II. Cardiovasc Intervent Radiol 2010; 33: 1044-8.




2020     |     www.medigraphic.com